Sheppard Mullin represented Littlejohn & Co. in the transaction. Littlejohn & Co. executed its acquisition of Sunbelt Modular, a leading designer and manufacturer of modular solutions....
You must be a Standard 1 Year member to access this content.
Sheppard Mullin represented Guardion Health Sciences in the transaction. Guardion Health Sciences, Inc. (NASDAQ: GHSI) announced the sale of its Viactiv business to Doctor’s Best Inc....
You must be a Standard 1 Year member to access this content.
Sheppard Mullin represented Meritage Homes Corporation in the transaction. Meritage Homes Corporation (NYSE: MTH), the fifth largest homebuilder in the U.S., executed its offering and sale...
You must be a Standard 1 Year member to access this content.
Simpson Thacher & Bartlett LLP and Osborne Clarke advised CBRE Group, Inc., while Sheppard Mullin Richter & Hampton LLP acted for J&J and Arlington Capital Partners....
You must be a Standard 1 Year member to access this content.
Houlihan Lokey, Inc. and Sheppard, Mullin, Richter & Hampton LLP served as advisors to Littlejohn on the transaction. Littlejohn & Co. LLC (“Littlejohn”) signed its agreement to...
You must be a Standard 1 Year member to access this content.
Simpson Thacher & Bartlett, Covington & Burling, and ArentFox Schiff are representing Mars, Incorporated while Sheppard Mullin is representing Kevin’s Natural Foods. Mars, Incorporated announced that it...
You must be a Standard 1 Year member to access this content.
Sheppard Mullin advised Arlington Capital Partners on the deal. Arlington Capital Partners, a Washington, DC-based private equity firm, announced it has, in partnership with the existing...
You must be a Standard 1 Year member to access this content.
Sheppard Mullin advised Arlington Capital Partners on the deal. Arlington Capital Partners (“Arlington Capital”) announced that they have closed on the sale of Molecular Products to...
You must be a Standard 1 Year member to access this content.
Sheppard Mullin advised Arlington Capital Partners on the deal. Arlington Capital Partners (“Arlington Capital”) announced that they have closed on the sale of Molecular Products to...
You must be a Standard 1 Year member to access this content.
